all report title image
  • Published On : Dec 2022
  • Code : CMI5423
  • Industry : Pharmaceutical
  • Pages : 162
  • Formats :

The global onychomycosis treatment market was valued at US$ 2,859.8 Mn in 2021 and is forecast to reach a value of US$ 4,185.4 Mn by 2028 at a CAGR of 5.7% between 2022 and 2028. The market is experiencing strong growth owing to the risk of onychomycosis in diabetic patient and growing geriatric population worldwide. Moreover, rise in demand for safe and effective treatment and increase in focus on the development of novel onychomycosis treatments is expected to boost the growth of the market. However, factors such as side effects of onychomycosis treatment and Availability of alternative treatment options are expected to hamper growth of the market.

Global Onychomycosis Treatment Market: Regional Insights

Based on geography, the onychomycosis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the rising prevalence of onychomycosis in adults/elderly population and increasing awareness among people about safe and effective treatment in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), fungal nail infections, onychomycosis, are very common. They may affect up to 14% of the general population. Fungal toenail infections are more common than fungal fingernail infections. This in turn is expected to increase the demand for onychomycosis treatment in the United States.

Asia Pacific is also expected to witness significant growth in the global onychomycosis treatment market due to the increasing prevalence of onychomycosis and growing geriatric population in the region. For instance, onychomycosis is found more frequently in elderly population, and in more males than females. India’s elderly population (aged 60 and above) is expected to reach 194 million in 2031 from 138 million in 2021, a 41 per cent increase over a decade, according to the National Statistical Office (NSO)’s Elderly in India 2021 report. This in turn is expected to increase demand for onychomycosis treatment in India.

Figure 1. Global Onychomycosis Treatment Market Share (%), by Region, 2022

Onychomycosis Treatment  | Coherent Market Insights

Global Onychomycosis Treatment Market Drivers:

Risk of onychomycosis in diabetic patient or increase in prevalence of diabetes across the globe is expected to boost growth of the global onychomycosis treatment market over the forecast period. For instance, onychomycosis is more common in diabetics than non-diabetics, and diabetics are at greater risk of serious complications from onychomycosis. According to the International Diabetes Federation (2021 report), around 537 million adults (20-79 years) are living with diabetes, 1 in 10. This number is expected to rise to reach 643 million by 2030 and 783 million by 2045. This in turn is expected to aid in the growth onychomycosis treatment market.

Growing geriatric population worldwide is expected to drive growth of the global onychomycosis treatment market during the forecast period. For instance, onychomycosis is found more frequently in adults and elderly population, and in more males than females. According to the World Health Organization (WHO), by 2030, one in six people in the world will be aged 60 years or over, and the world’s population of people aged 60 years and older will double (around 2.1 billion) by 2050. Globally, the population aged 65 and over is growing faster than all other age groups. This in turn is also expected to propel the growth of the market.

Global Onychomycosis Treatment Market Opportunities:

Rise in demand for safe and effective onychomycosis treatment is expected to provide significant growth opportunities for players in the global onychomycosis treatment market. For instance, with the increase in incidence of onychomycosis and increase in awareness among people, the demand for safe and effective treatment is also increasing. In July 2021, Lupin received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market a drug (Tavaborole Topical Solution) to treat Onychomycosis. It is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or mentagrophytes.

Increase in focus on the development of novel/innovative onychomycosis treatments is expected to provide lucrative growth opportunities for players in the onychomycosis treatment market. For instance, players in the market are focusing on launching novel/innovative treatments in the market for safe and effective onychomycosis treatment. In April 2020, TheOTCLab launched the FungeX range for innovative nail fungus treatments. The product was unique and patented application and provides eight hours of treatment while patients suffering from onychomycosis were asleep. This in turn is expected to propel the growth of the market.

CMI table icon

Onychomycosis Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 2,859.8 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 5.7% 2028 Value Projection: US$ 4,185.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type: Drugs, Laser Therapy, and Photodynamic Therapy
  • By Type: Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, and Other Types
Companies covered:

Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.

Growth Drivers:
  • Risk of onychomycosis in diabetic patient
  • Growing geriatric population worldwide
Restraints & Challenges:
  • Side effects of onychomycosis treatment
  • Availability of alternative treatment options

Global Onychomycosis Treatment Market Trends:

With the increase in demand for safe and effective treatment, the number of clinical trials around the world is also increasing with the rapid pace. Players in the market are focusing on conducting clinical trials to expand their product portfolio. Market players are launching safe, effective, novel onychomycosis treatments to treat onychomycosis. This trend is expected to continue during the forecast period, driving the growth of the market.

Moreover, one of the major trend driving the onychomycosis treatment market growth is the rise in prevalence of onychomycosis and rise in awareness among people. For instance, several studies have shown that the prevalence of onychomycosis increases with the age, possibly due to diabetes mellitus, poor peripheral circulation, prolonged exposure to pathogenic fungi, and repeated nail trauma, among others. This trend is also expected to continue during the forecast period, driving the growth of the global onychomycosis treatment market.

Global Onychomycosis Treatment Market Restraints:

Side effects of onychomycosis treatment (onychomycosis drugs) is expected to hamper the growth of the global onychomycosis treatment market. For instance, the most commonly used oral drugs for onychomycosis treatment are terbinafine, griseofulvin, ketoconazole, and itraconazole, among others. Some of the most common side effects are redness, rash, itching, mild burning sensations, feeling sick, diarrhea, indigestion, abdominal pain, and change in taste. However, these side effects are usually mild and only last for a short period of time.

Availability of alternative treatment options is expected to hinder growth of global onychomycosis treatment market. For instance, availability of alternative treatment options, such as tea tree oil and Vicks Vapour Listerine for the treatment of nail infections is also expected to restrain the growth of the global onychomycosis treatment market.

Figure 2. Global Onychomycosis Treatment Market Share (%), by Treatment Type, 2022

Onychomycosis Treatment  | Coherent Market Insights

Global Onychomycosis Treatment Market Segmentation:

The global onychomycosis treatment market report is segmented into Treatment Type, Type, and Geography.

Based on Treatment Type, the onychomycosis treatment market is segmented into Drugs, Laser Therapy, and Photodynamic Therapy. Out of which, Drugs Segment is expected to dominate the onychomycosis treatment market over the forecast period and this is attributed to the increase in demand for onychomycosis drugs. Onychomycosis drugs are typically the first-line treatment for confirmed onychomycosis.

Laser Therapy Segment is also expected to witness significant growth in the near future and this is due to the increase in preference for laser therapy. Laser treatment offers more promising therapy to treat onychomycosis in diabetics, elderly patients with drug intolerance, and people with kidney and liver disease due to lesser side effects associated with it.

Based on Type, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, and Other Types. Out of which, Distal Subungual Onychomycosis Segment is expected to dominate the market over the forecast period and this is attributed to the rise in prevalence of onychomycosis. Distal subungual onychomycosis (DSO) is the most common form of onychomycosis.

White Superficial Onychomycosis Segment is also expected to witness significant growth in the near future and this is owing to the increase in cases of white superficial onychomycosis. It is most frequently seen in toenails and is primarily caused by T. mentagrophytes, which possess enzymes that allow it to digest and invade the nail plate directly.

Global Onychomycosis Treatment Market: Key Developments

In April 2020, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for JUBLIA (efinaconazole) topical solution, 10%, to treat onychomycosis, a fungal infection of the toenails.

In June 2019, Galderma SA, and the European Society for Dermatological Research (ESDR) and healthcare companies LEO Pharma and Celgene, joined forces to find the Skin Science Foundation (SSF) in Geneva, Switzerland. This will accelerate next generation skincare by using cutting-edge science to better understand skin health and its transition to disease.

Global Onychomycosis Treatment Market: Key Companies Insights

The global onychomycosis treatment market is highly competitive. This is attributed to the rise in demand for safe and effective treatment, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global onychomycosis treatment market are Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.

*Definition: Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit. For onychomycosis treatment, drugs remain the first-line treatment choice and hold a major market share owing to a consistently high success rate.

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit. For treatment, drugs remain the first-line treatment choice owing to a consistently high success rate. A newer generation of oral antifungal agents (itraconazole and terbinafine) has replaced older therapies in the treatment of onychomycosis.

Market Dynamics:

Risk of onychomycosis in diabetic patient or increase in prevalence of diabetes, growing geriatric population, increase in demand for safe and effective treatment, rise in focus on the development of novel onychomycosis treatments, and growing awareness among people about potential threats of onychomycosis and available treatments are major factors expected to drive growth of the global onychomycosis treatment market over the forecast period.

For instance, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.

Moreover, in October 2020, Mundipharma launched the latest addition to its BETADINE range of infectious disease therapies. This BETADINE EMTRIX fungal nail solutions effectively treats the onychomycosis and improves the nail appearance after regular application.

Key features of the study:

  • This report provides in-depth analysis of the global onychomycosis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global onychomycosis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global onychomycosis treatment market.

Detailed Segmentation:

  • Global Onychomycosis Treatment Market, By Treatment Type:
    • Drugs
    • Laser Therapy
    • Photodynamic Therapy
  • Global Onychomycosis Treatment Market, By Type:
    • Distal Subungual Onychomycosis
    • White Superficial Onychomycosis
    • Proximal Subungual Onychomycosis
    • Other Types
  • Global Onychomycosis Treatment Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Lumenis Ltd.
    • Cipla Ltd.
    • Bayer AG
    • Johnson & Johnson
    • Moberg Pharma AB
    • Pfizer Inc.
    • Novartis
    • Galderma SA
    • Reddys Laboratories Ltd.
    • Medimetriks Pharmaceuticals Inc.
    • Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)

Frequently Asked Questions

The global onychomycosis treatment market size is estimated to be valued at US$ 3,008.5 Million in 2022 and is expected to exhibit a CAGR of 5.7% between 2022 and 2028.
Risk of onychomycosis in diabetic patient and growing geriatric population worldwide is fueling the market.
Drugs segment is the leading treatment type segment in the market.
Side effects of onychomycosis treatment and availability of alternative treatment options are major factors restraining the market.
Major players operating in the market are Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo